RhumbLine Advisers’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

RhumbLine Advisers’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-80,564	Closed	-$92K	–	3294
2022 Q1	$92K	Buy	80,564 +5,742	+8%	+$6.86K	﹤0.01%	2900
2021 Q4	$168K	Sell	74,822 -1,006	-1%	-$2.52K	﹤0.01%	2872
2021 Q3	$259K	Buy	75,828 +4,289	+6%	+$13.2K	﹤0.01%	2822
2021 Q2	$214K	Buy	+71,539	New	+$226K	﹤0.01%	2909
2017 Q2	–	Sell	-65,077	Closed	-$210K	–	2970
2017 Q1	$210K	Buy	65,077 +17,452	+37%	+$42.9K	﹤0.01%	2638
2016 Q4	$64K	Sell	47,625 -34,964	-42%	-$45.7K	﹤0.01%	2818
2016 Q3	$129K	Buy	82,589 +700	+0.9%	+$1.07K	﹤0.01%	2774
2016 Q2	$109K	Buy	81,889 +27,897	+52%	+$130K	﹤0.01%	2905
2016 Q1	$285K	Buy	53,992 +420	+0.8%	+$2.57K	﹤0.01%	2553
2015 Q4	$421K	Buy	53,572 +4,420	+9%	+$38.1K	﹤0.01%	2359
2015 Q3	$415K	Sell	49,152 -259	-0.5%	-$2.39K	﹤0.01%	2361
2015 Q2	$541K	Sell	49,411 -2,115	-4%	-$27.1K	﹤0.01%	2272
2015 Q1	$720K	Buy	51,526 +6,375	+14%	+$97.5K	﹤0.01%	2068
2014 Q4	$763K	Sell	45,151 -850	-2%	-$12.4K	﹤0.01%	1989
2014 Q3	$617K	Sell	46,001 -100	-0.2%	-$1.19K	﹤0.01%	2081
2014 Q2	$587K	Buy	46,101 +52	+0.1%	+$542	﹤0.01%	2166
2014 Q1	$548K	Sell	46,049 -2,340	-5%	-$31.4K	﹤0.01%	2164
2013 Q4	$668K	Sell	48,389 -2,100	-4%	-$29.7K	﹤0.01%	2073
2013 Q3	$881K	Buy	50,489 +1,323	+3%	+$25.3K	﹤0.01%	1863
2013 Q2	$799K	Buy	+49,166	New	+$1.52M	﹤0.01%	1916

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RhumbLine Advisers's INFI Position: Q2 2022 in Review

RhumbLine Advisers sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2022, closing a stake of 80,564 shares — an estimated $92K sold.

RhumbLine Advisers first reported a position in INFI in Q2 2013 and held it in 20 quarters. The position peaked at $881K in Q3 2013. 77 funds tracked by Wall St. Rank hold INFI as of Q2 2022.

RhumbLine Advisers reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 80,564 Infinity Pharmaceuticals, Inc. shares in Q2 2022, an estimated $92K.
RhumbLine Advisers first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 20 quarters.
RhumbLine Advisers's Infinity Pharmaceuticals, Inc. position peaked at $881K in Q3 2013.
77 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.